Major new funding for research into epilepsy is announced
10 January 2012
The EpiPGX Consortium, coordinated by UCL Institute of Neurology's Professor Sanjay Sisodiya,and involving 15 partners from 8 countries, has
received almost €6 million funding from the European Union FP7 programme
to investigate the genetic basis of responses to antiepileptic drugs
(AEDs) in epilepsy.
Over 50,000,000 people across the world have
epilepsy. For many people, AEDs are simply not available, or the choice
is extremely limited. In other countries, several AEDs are available to
be prescribed, but the evidence guiding choice of drug for an
individual patient is very limited. The EpiPGX Consortium will explore
the influence of genetic variation on responses, both desirable and
undesirable, to AEDs, aiming to identify genetic variants that will
guide treatment choices at the individual level.
The Consortium is coordinated by Professor Sanjay Sisodiya (Department of Clinical and Experimental Epilepsy), with the following partners: Université Libre de Bruxelles (Belgium),
Istituto Giannina Gaslini (Italy), Eberhard Karls Universitaet Tuebingen
(Germany), Stichting Epilepsie Instellingen Nederland (The
Netherlands), Universitaetsklinikum Bonn (Germany), Royal College of
Surgeons in Ireland (Ireland), Belfast Health and Social Care Trust
(UK), Islensk Erfdagreining EHF (Iceland), Universite Du Luxembourg
(Luxembourg), Universitair Medisch Centrum Utrecht (The Netherlands),
The University of Liverpool (UK), Imperial College of Science,
Technology and Medicine (UK), University of Glasgow (UK) and GABO:mi
Gesellschaft fur Ablauforganisation:milliarium mbH & Co. KG
(Germany).
The Consortium welcomes collaboration. Please contact Professor Sisodiya for further information.
Links:
